UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1032-13
Program Prior Authorization/Notification
Medications Firazyr® (icatibant)*, icatibant, Sajazir™ (icatibant)*
P&T Approval Date 11/2011, 11/2012, 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018,
7/2019, 7/2020, 7/2021, 7/2022, 4/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Firazyr (icatibant)* is a bradykinin B2 receptor antagonist indicated for treatment of acute
attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Sajazir (icatibant)*
injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of HAE
in adults 18 years of age and older.
2. Coverage Criteriaa:
A. Firazyr*, icatibant, or Sajazir* will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. Prescribed for the treatment of acute HAE attacks
-AND-
3. Not used in combination with other products indicated for the acute treatment of HAE
attacks (e.g., Berinert, Kalbitor, or Ruconest)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Firazyr (brand) and Sajazir are typically excluded from coverage. Coverage reviews may be in
place if required by law or the benefit plan.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
© 2025 UnitedHealthcare Services, Inc.
1
4. References:
1. Firazyr [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; January 2024.
2. Sajazir [package insert]. Cambridge, CB3 0FA, United Kingdom: Cycle Pharmaceuticals Ltd;
February 2024.
Program Prior Authorization/Notification - Firazyr (icatibant), Sajazir (icatibant)
Change Control
11/2013 Annual review. Removed requirement for Type I or II HAE. Changed
authorization duration from 12 months to 60 months.
8/2014 Annual review. Added an additional criterion that does not allow
combination use with other HAE acute treatments. Decreased authorization
from 60 months to 12 months. Updated Background and References.
8/2015 Annual review. No change.
7/2016 Annual review with no changes to the clinical criteria. Updated background
and references.
7/2017 Annual review. No changes to program.
7/2018 Annual review. No changes to program.
7/2019 Annual review. No changes to program.
7/2020 Annual review. No changes to coverage criteria.
7/2021 Annual review. No changes to coverage criteria. Reference updated.
7/2022 Annual review with no changes to coverage criteria. Added state mandate
footnote. Updated reference.
4/2023 Added Sajazir, updated background, and updated references.
2/2024 Added coverage exclusion statement for brand Firazyr and Sajazir. Revised
wording of criteria without changes to clinical intent.
2/2025 Annual review with no changes to coverage criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2